

Fabienne THOMAS JEAN

Pharm.D, Ph.D

Institut Universitaire du Cancer Toulouse – Oncopole
Laboratoire de Biologie Médicale Oncologique - Secteur Pharmacologie
1 avenue Irène Joliot-Curie
31059 TOULOUSE Cedex 9 - FRANCE

thomas.fabienne@iuct-oncopole.fr

☎ : 05 31 15 52 19

Associate Professor in Pharmacology at the School of Pharmacy, University of Toulouse
Biologist in Pharmacology Laboratory of Institut Claudius Regaud, Cancer Institute,
Toulouse, France

EDUCATION

| | |
|------------------|---|
| 2016 | HDR (Habilitation to conduct researches) |
| 2005-2007 | PhD in Pharmacology with honors. Title: Mechanism of action and resistance of erlotinib in head and neck squamous cell carcinoma". Supervisors: Dr JP Delord and Dr P.Canal |
| 2007 | Pharmacy degree (Pharm.D) with honors. Toulouse III-Paul Sabatier University, France |
| 2003-2007 | Resident in pharmaceutical internship |
| 2004 | DEA " <i>Innovation Pharmacologique</i> " equivalent to a master's degree in Pharmacology |

TEACHING ACTIVITY

Since 2008 **Associate professor in PHARMACOLOGY at the Faculty of Pharmaceutical Sciences** in Toulouse, Université Paul Sabatier

RESEARCH ACTIVITY

| | |
|------------------|---|
| 2003-2016 | Team EA4553 « Individualisation des traitements des cancers ORL et ovariens », supervised by Pr Etienne Chatelut et Pr JP Delord. |
| 2010 | 10 months fellowship at the Institute of Pharmacogenomics and Individualized Therapy, University of North Carolina (NC, USA) under Dr Howard McLeod supervision: « Pharmacogenomic factors involved in rectal tumors response to radiochemotherapy. » |
| 2016- | Team DIAD of CRCT (Centre de Recherche en Cancérologie de Toulouse) Inserm/Université de Toulouse III - Paul Sabatier (UMR1037): « Dose individualization of anticancer drugs ». |

AWARDS

- ❖ **Young scientist Prize for the best oral presentation** at the 14th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Rotterdam, The Netherlands, 2015 for: "Lethal toxicity of 5-fluorouracil in the era of personalized therapy: discovery of a novel mutation disrupting the dihydropyrimidine deshydrogenase activity."
- ❖ **PEDR (Prime d'Encadrement Doctoral et de Recherche) for 2019-2022.**

RESEARCH SUPERVISION ACTIVITY

| Level | Number of students |
|--|--------------------|
| Master 1 | 20 |
| Master 2 | 8 |
| Doctorat d'Etat en Pharmacie (Pharm.D) | 6 |
| Doctorat en Sciences (Ph.D) | 4 + 1 ongoing |

MEMBERSHIPS

- Chair of GPCO (Group of Clinical Pharmacology in Oncology- Unicancer) since March 2019.
- Member of the French National network of Pharmacogenetics RNPgX
- Member of « Société Française de Pharmacologie et Thérapeutique » (Therapeutic Drug Monitoring group)
- Member of IATDMCT (International Association for Therapeutic Drug Monitoring and Clinical Toxicology)

PUBLICATIONS & COMMUNICATIONS

H-index = 21

| | |
|---|---|
| <i>International journals (ACL)</i> | <i>56 (15 as 1st author, 3 as 2nd author and 12 as last author)</i> |
| <i>National journals (ACLN)</i> | <i>7 (3 as 1st author)</i> |
| <i>Book chapters (OS-OV)</i> | <i>5</i> |
| <i>Invited talks (INV)</i> | <i>7</i> |
| <i>Patents</i> | <i>3</i> |
| <i>Oral communications in International conferences as speaker (ACTI)</i> | <i>6</i> |
| <i>Oral communications in national conferences as speaker (ACTN)</i> | <i>2</i> |
| <i>Posters (AFF)</i> | <i>27</i> |

(ACL) Publications dans des revues internationales ou nationales avec comité de lecture, répertoriées dans les bases de données internationales

- ACL 1. **Thomas FJ**, McLeod HL, Watters JW. Pharmacogenomics: the influence of genomic variation on drug response. *Curr Top Med Chem* 2004; 4(13):1399-1409. **IF=4.4**
- ACL 2. Chevreau C, **Thomas F**, Couteau C, Dalenc F, Mourey L, Chatelut E. Ototoxicity of high-dose carboplatin. *J Clin Oncol* 2005; 23(15):3649-3650. **IF=11.8**
- ACL 3. Hoppe A, Seronie-Vivien S, **Thomas F**, Delord JP, Malard L, Canal P, Chatelut E. Serum cystatin C is a better marker of topotecan clearance than serum creatinine. *Clin Cancer Res* 2005; 11(8):3038-3044. **IF=5.7**
- ACL 4. **Thomas F**, Seronie-Vivien S, Gladiéff L, Dalenc F, Durrand V, Malard L, Lafont T, Poublanc M, Bugat R, Chatelut E. Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin. *Clin Pharmacokinet* 2005; 44(12):1305-1316. **IF=5.2**
- ACL 5. Balin-Gauthier D, Delord JP, Rochemaix P, Mallard V, **Thomas F**, Hennebelle I, Bugat R, Canal P, Allal C. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in

human colorectal tumor cell lines expressing different level of EGFR. *Cancer Chemother Pharmacol* 2006; 57(6):709-718. **IF=2.4**

- ACL 6. Seronie-Vivien S, Toullec S, Malard L, **Thomas F**, Durrand V, Chatelut E. Contribution of the MDRD equation and of cystatin C for renal function estimates in cancer patients. *Med Oncol* 2006; 23(1):63-73. **IF=1,3**
- ACL 7. **Thomas F**, Rochaix P, Benlyazid A, Sarini J, Rives M, Lefebvre JL, Allal BC, Courbon F, Chatelut E, Delord JP. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. *Clin Cancer Res* 2007; 13(23):7086-7092. **IF=6.25**
- ACL 8. **Thomas F**, Seronie-Vivien S, Malard L, Chatelut E. [Interest of cystatin C for individual dosing of anticancer drugs cleared by the kidneys]. *Thérapie* 2007; 62(2):121-127. **IF=0.4**
- ACL 9. **Thomas F**, Nicot F, Sandres-Saune K, Dubois M, Legrand-Abrevanel F, Alric L, Peron JM, Pasquier C, Izopet J. Genetic diversity of HCV genotype 2 strains in south western France. *J Med Virol* 2007; 79(1):26-34. **IF=2.8**
- ACL 10. Gesson-Paute A, Ferron G, **Thomas F**, de Lara EC, Chatelut E, Querleu D. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study. *Ann Surg Oncol* 2008; 15(1):339-344. **IF=3.9**
- ACL 11. **Thomas F**, Ferron G, Gesson-Paute A, Hristova M, Lochon I, Chatelut E. Increased tissue diffusion of oxaliplatin during laparoscopically assisted versus open heated intraoperative intraperitoneal chemotherapy (HIPEC). *Ann Surg Oncol* 2008; 15(12):3623-3624. **IF=3.9**
- ACL 12. **Thomas F**, Rochaix P, White-Koning M, Hennebelle I, Sarini J, Benlyazid A, Malard L, Lefebvre JL, Chatelut E, Delord JP. Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. *Eur J Cancer* 2009; 45(13):2316-2323. **IF=4.1**
- ACL 13. Ferron G, Martinez A, Mery E, Querleu D, **Thomas F**, Chatelut E, Gladiéff L. [Importance of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer]. *Bull Cancer* 2009; 96(12):1243-1252. **IF=0.8**
- ACL 14. Georger B, Hargrave D, **Thomas F**, Ndiaye A, Frappaz D, Andreiuolo F, Varlet P, Aerts I, Riccardi R, Jaspan T, Chatelut E, Le Deley MC, Paoletti X, Saint-Rose C, Leblond P, Morland B, Gentet JC, Meresse V, Vassal G. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. *Neuro Oncol* 2010. **IF=5.7**
- ACL 15. Vergez S, Delord JP, **Thomas F**, Rochaix P, Caselles O, Filleron T, Brillouet S, Canal P, Courbon F, Allal BC. Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer. *Clin Cancer Res* 2010; 16(17):4434-4445. **IF=7.3**
- ACL 16. **Thomas F**, Hoskins JM, Dvorak A, Tan BR, McLeod HL. Detection of the G>C SNP and rare mutations in the 28-bp repeat of *TYMS* using gel-based capillary electrophoresis. *Pharmacogenomics*. 2010 Dec;11(12):1751-6. **IF=3.9**
- ACL 17. Tan BR, **Thomas F**, Myerson RJ, Zehnbauser B, Trinkaus K, Malyapa RS, Mutch MG, Abbey EE, Alyasiry A, Fleshman JW, McLeod HL. Thymidylate Synthase Genotype-Directed Neoadjuvant Chemoradiation for Patients With Rectal Adenocarcinoma. *J Clin Oncol*. 2011 Jan 4. **IF=18.4**

- ACL 18. White-Koning M, Civade E, Geoerger B, **Thomas F**, Le Deley MC, Hennebelle I, et al. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. *Clin Cancer Res* 2011; Jul 15;17(14):4862-71. **IF=7.7**
- ACL 19. **Thomas F**, Motsinger-Reif AA, Hoskins JM, Dvorak A, Roy S, Alyasiri A, Myerson RJ, Fleshman JW, Tan BR, McLeod HL. Methylenetetrahydrofolatereductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. *Br J Cancer*. 2011 Nov 22; 105(11):1654-62. **IF=5.0**
- ACL 20. **Thomas F**, Delmar P, Vergez S, Rochaix P, Hennebelle I, McLoughlin P, Benlyazid A, Sarini J, Delord JP. Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma. *Head Neck*. 2013 Jun;35(6):809-18. **IF=3.0**
- ACL 21. Laurenty AP*, **Thomas F***, Chatelut E, Bétrian S, Le Guellec C, Hennebelle I, Le Guellec S, Chevreau C. Irreversible Hepatotoxicity after administration of Trabectedin to a Pleiomorphic Sarcoma Patient with ABCC2 rare polymorphism: a case report. *Pharmacogenomics*. 2013 Sep;14(12):1389-96. **IF=3.4**
- * Authors contributed equally
- ACL 22. Boyer JC, Etienne-Grimaldi MC, **Thomas F**, Quaranta S, Picard N, Lorient MA, Poncet D, Gagnieu MC, Ged C, Broly F, Le Morvan V, Bouquié R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C. Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan. *Bull Cancer*. 2014 Jun 1;101(6):533-553. **IF=0.6**
- ACL 23. Etienne-Grimaldi MC, Boyer JC, **Thomas F**, Quaranta S, Picard N, Lorient MA, Narjoz C, Poncet D, Gagnieu MC, Ged C, Broly F, Le Morvan V, Bouquié R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C; Collective work by Groupe de Pharmacologie Clinique Oncologique (GPCO-Unicancer); French Réseau National de Pharmacogénétique Hospitalière (RNPGx). UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. *Fundam Clin Pharmacol*. 2015 Jun;29(3):219-37. **IF=2.1**
- ACL 24. Mbatchi LC, Schmitt A, **Thomas F**, Cazaubon Y, Robert J, Lumbruso S, Brouillet JP, Pourquier P, Chatelut E, Boyer JC, Evrard A. Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination. *Pharmacogenomics*. 2015;16(13):1439-50. **IF=3.2**
- ACL 25. Dhelens C, Bonadona A, **Thomas F**, Chapuis C, Potton L, Marsili S, Bedouch P, Schwebel C. Lethal 5-fluorouracil toxicity in a colorectal patient with severe dihydropyrimidine dehydrogenase (DPD) deficiency. *Int J Colorectal Dis*. 2016;31(3):699-701. **IF=2.4**
- ACL 26. **Thomas F**, Hennebelle I, Delmas C, Lochon I, Dhelens C, Garnier Tixidre C, Bonadona A, Penel N, Goncalves A, Delord JP, Toulas C, Chatelut E. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio. *Clin Pharmacol Ther*. 2016 Feb;99(2):235-42. **IF=7.9**
- ACL 27. Imbs DC, Paludetto MN, Négrier S, Powell H, Lafont T, White-Koning M, Chatelut E, **Thomas F**. Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site. *Invest New Drugs*. 2016 Feb;34(1):41-8. **IF=2.9**
- ACL 28. Mbatchi LC, Robert J, Ychou M, Boyer JC, Del Rio M, Gassiot M, **Thomas F**, Tubiana N, Evrard A. Effect of single nucleotide polymorphisms in the xenobiotic-sensing receptors NR1I2 and NR1I3 on the pharmacokinetics and toxicity of irinotecan in colorectal cancer patients. *Clin Pharmacokinet*. 2016 Apr 26. **IF=5.05**

- ACL 29. C Sauzay, M White-Koning, I Hennebelle, T Deluche, C Delmas, DC Imbs, E Chatelut, **F Thomas**. Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin. *Pharmacol Res.* 2016 Aug;110:89-95. **IF=4.4**
- ACL 30. **Thomas F**. Reply to the letter addressed by Amr A. EL-Arabey "Dual function of OCT-2 and MATE1 in Cisplatin induced nephrotoxicity". *Pharmacol Res.* 2017 May;119:494. **IF=4.4**
- ACL 31. Picard N, Boyer JC, Etienne-Grimaldi MC, Barin-Le Guellec C, **Thomas F**, Lorient MA; French National Network of Pharmacogenetics (RNPgX). Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPgX). *Therapie.* 2017 Apr;72(2):185-192. Review. **IF=0.93**
- ACL 32. Quaranta S, **Thomas F**. Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics. *Therapie.* 2017 Apr;72(2):205-215. Review. **IF=0.93**
- ACL 33. Etienne-Grimaldi MC, Le Guellec CB, Boyer JC, Chatelut E, Evrard A, Lorient MA, Paci A, Royer B, **Thomas F**, Ciccolini J. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing. *Semi Oncol.* 2017 Apr;44(2):159-160. **IF=6.2**
- ACL 34. Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, **Thomas F**, Chatelut E, Merlin JL, Pinguet F, Ferrand C, Meijer J, Evrard A, Llorca L, Romieu G, Follana P, Bachelot T, Chaigneau L, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roché H, Bonnetterre J, Servent V, Dohollou N, Château Y, Chamorey E, Desvignes JP, Salgado D, Ferrero JM, Milano G. New advances in DPYD genotype and risk of severe toxicity under capecitabine. *PLoS One.* 2017 May 8;12(5):e0175998. **IF=2.8**
- ACL 35. Moeung S, Chevreau C, Broutin S, Guitton J, Lelièvre B, Ciccolini J, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Paci A, Marsili S, Malard L, Chatelut E, **Thomas F**. Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study. *Clin Cancer Res.* 2017 Sep 19. **IF=9.6**
- ACL 36. Segala G, David M, de Medina P, Poirot MC, Serhan N, Vergez F, Mougel A, Saland E, Carayon K, Leignadier J, Caron N, Voisin M, Cherier J, Ligat L, Lopez F, Noguier E, Rives A, Payré B, Saati TA, Lamaziere A, Despres G, Lobaccaro JM, Baron S, Demur C, de Toni F, Larrue C, Boutzen H, **Thomas F**, Sarry JE, Tosolini M, Picard D, Record M, Récher C, Poirot M, Silvente-Poirot S. Dendrogenin A drives LXR to trigger lethal autophagy in cancers. *Nat Commun.* 2017 Dec 4;8(1):1903.
- ACL 37. Lorient MA, Ciccolini J, **Thomas F**, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPgX networks]. *Bull Cancer.* 2018 Apr;105(4):397-407.
- ACL 38. **Thomas F**, Veal GJ, El Balkhi S, Lafont T, Picard N, Brugières L, Chatelut E, Piguier C. Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. *Cancer Chemother Pharmacol.* 2018 Jun 19.
- ACL 39. García-González X, López-Tarruella S, García MI, González-Haba E, Blanco C, Salvador-Martin S, Jerez Y, **Thomas F**, Jarama M, Sáez MS, Martín M, López-Fernández LA. Severe toxicity to capecitabine due to a new variant at a donor splicing site in the

dihydropyrimidine dehydrogenase (DPYD) gene. *Cancer Manag Res.* 2018 Oct 11; 10:4517-4522.

- ACL 40. Moeung S, Chevreau C, Poinsignon V, Guitton J, Lelièvre B, Ciccolini J, Gladieff L, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Delahousse J, Filleron T, Lochon I, Chatelut E, **Thomas F**. Estimation of unbound carboplatin clearance from total plasma concentrations as a means of facilitating therapeutic drug monitoring. *Ther Drug Monit.* 2019 Feb;41(1):66-74.
- ACL 41. Puszkiel A, Arellano C, Vachoux C, Evrard A, Le Morvan V, Boyer JC, Robert J, Delmas C, Dalenc F, Debled M, Venat-Bouvet L, Jacot W, Suc E, Sillet Bach I, Filleron T, Roché H, Chatelut E, White-Koning M*, **Thomas F***. Factors affecting tamoxifen metabolism in breast cancer patients; preliminary results of the French PHACS study (NCT01127295). *Clin Pharmacol Ther.* 2019 Sep;106(3):585-595.* Authors shared seniorship
- ACL 42. Le Louedec F, Alix-Panabières C, Lafont T, Allal BC, Garrel R, Digue L, Guigay J, Cupissol D, Delord JP, Lallemand B, Alfonsi M, Aubry K, Mazel M, Becher F, Perriard F, Chatelut E, **Thomas F**. Cetuximab Pharmacokinetic/Pharmacodynamics relationships in advanced head and neck carcinoma patients. *Br J Clin Pharmacol.* 2019 Jun;85(6):1357-1366
- ACL 43. Loriot MA, Masskouri F, Carni P, Le Malicot K, Seitz JF, Michel P, Legoux JL, Bouché O, André T, Faroux R, Delalogue S, Malka D, Guigay J, Thariat J, **Thomas F**, Barin-Le-Guellec C, Ciccolini J, Boyer JC, Étienne-Grimaldi MC. [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists]. *Bull Cancer.* 2019 Sep;106(9):759-775. French.
- ACL 44. Moeung S, Chevreau C, Marsili S, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Filleron T, Delmas C, Lafont T, Chatelut E, **Thomas F**. Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors. *Pharm Res.* 2020 Jul 16;37(7):147.
- ACL 45. García-González X, Kaczmarczyk B, Abarca-Zabalía J, **Thomas F**, García-Alfonso P, Robles L, Pachón V, Vaz Á, Salvador-Martín S, Sanjurjo-Sáez M, López- Fernández LA. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine. *Cancer Chemother Pharmacol.* 2020 Jul;86(1):45-54.
- ACL 46. Gallais F, Ysebaert L, Despas F, De Barros S, Dupré L, Quillet-Mary A, Protin C, **Thomas F**, Obéric L, Allal B, Chatelut E, White-Koning M. Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies. *Clin Pharmacokinet.* 2020 Apr 24.
- ACL 47. Maillard M, Chevreau C, Le Louedec F, Cassou M, Delmas C, Gourdain L, Blay JY, Cupissol D, Bompas E, Italiano A, Isambert N, Delcambre-Lair C, Penel N, Bertucci F, Guillemet C, Plenecassagnes J, Foulon S, Chatelut E, Le Cesne A, **Thomas F**. Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma. *Cancers (Basel).* 2020 Dec 4;12(12):3647.
- ACL 48. Lunar N, Etienne-Grimaldi MC, Macaire P, **Thomas F**, Dalenc F, Ferrero JM, Pivot X, Milano G, Royer B, Schmitt A. Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients. *Cancer Chemother Pharmacol.* 2021 Feb;87(2):229-239.
- ACL 49. Puszkiel A, Arellano C, Vachoux C, Evrard A, Le Morvan V, Boyer JC, Robert J, Delmas C, Dalenc F, Debled M, Venat-Bouvet L, Jacot W, Dohollou N, Bernard-Marty C, Laharie-Mineur H, Filleron T, Roché H, Chatelut E, **Thomas F***, White-Koning M*. Model-Based

Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer. Clin Pharmacol Ther. 2021 May;109(5):1244-1255. * Authors shared seniorship

- ACL 50. Maillard M, Le Louedec F, **Thomas F**, Chatelut E. Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a review. Expert Opin Drug Metab Toxicol. 2020 Oct;16(10):907-925.
- ACL 51. Le Louedec F, Gallais F, **Thomas F**, White-Koning M, Allal B, Protin C, Ysebaert L, Chatelut É, Puisset F. Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data. Pharmaceuticals (Basel). 2021 Feb 18;14(2):162.
- ACL 52. Maillard M, Eche-Gass A, Ung M, Brice A, Marsili S, Montastruc M, Puisset F, **Thomas F**. Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines. Cancer Chemother Pharmacol. 2021 Apr;87(4):579-583.
- ACL 53. Chevreau C, Massard C, Flechon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Fizazi K, Mourey L, Paci A, Guitton J, **Thomas F**, Lelièvre B, Ciccolini J, Moeung S, Gallois Y, Olivier P, Culine S, Filleron T, Chatelut E. Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. Cancer Med. 2021 Apr;10(7):2250-2258.
- ACL 54. **Thomas F**, Maillard M, Launay M, Tron C, Etienne-Grimaldi MC, Gautier-Veyret E, Haufroid V, Pallet N, Royer B, Narjoz C, Schmitt A; Groupe de Pharmacologie Clinique Oncologique (GPCO-UNICANCER). Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation. Ann Oncol. 2021 Jun;32(6):810-811.
- ACL 55. Malier M, Gharzeddine K, Laverriere MH, Marsili S, **Thomas F**, Decaens T, Roth G, Millet A. Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer. Cancer Res. 2021 Dec 1;81(23):5963-5976.
- ACL 56. Maillard M, Louveau B, Vilquin P, Goldwirt L, **Thomas F***, Mourah S*. Pharmacogenomics in solid cancers and hematologic malignancies: Improving personalized drug prescription. Therapie. 2021 Nov 25:S0040-5957(21)00241-9. * co-seniors authors

ACLN : Articles dans des revues avec comité de lecture non répertoriées dans des bases de données internationales.

- ACLN 1. **Thomas F**, Chatelut E. Platinum Compounds. Oncologie 2007; 9(11):741-745.
- ACLN 2. **Thomas F**, Chatelut E. Individualisation des doses en Oncologie. La Lettre du Pharmacologue, juillet 2008
- ACLN 3. Civade E, **Thomas F**. Nouvelles cibles des médicaments anti-cancéreux. La Lettre du Pharmacologue. Vol. 24 - n° 4 - octobre-novembre-décembre 2010
- ACLN 4. **Thomas F**. Pharmacogénétique et tamoxifène dans le cancer du sein : où en est-on? La Lettre du Pharmacologue • Vol. 29 - n° 2 - avril-mai-juin 2015.
- ACLN 5. Picard N, Boyer JC, Etienne-Grimaldi MC, Barin-Le Guellec C, **Thomas F**, Lorient MA; Réseau national de pharmacogénétique (RNPGx). Traitements personnalisés grâce à la pharmacogénétique : niveaux de preuve et de recommandations du Réseau national de pharmacogénétique (RNPGx). Therapie. 2017 Apr;72(2):175-183.

- ACLN 6. Quaranta S, **Thomas F.** Pharmacogénétique des médicaments anticancéreux : état des connaissances et des pratiques – recommandations du Réseau national de pharmacogénétique (RNPGx). *Thérapie*. 2017 Apr;72(2):193-204.
- ACLN 7. Maillard M, Narjoz C, Lorient MA, **Thomas F.** Dépistage du déficit de la dihydropyrimidine déshydrogénase : une prévention de la toxicité des fluoropyrimidines. *Revue de Biologie Médicale* N° 351 – Nov-Déc 2019

OS : Scientific Books/chapters.

OS 1. Ouvrage : « Thérapies ciblées en cancérologie ». Coordonnateurs : David Azria et Jean-Philippe Spano. Edition John LibbeyEurotext – 2006.

Chapitre : « *Les inhibiteurs de l'activité tyrosine kinase du récepteur à l'EGF : modes d'action et molécules en développement.* » JP Delord et **F Thomas**

OS 2. Ouvrage: « Platinum and others Heavy Metal Compounds in Cancer Chemotherapy. Molecular Mechanisms and Clinical Applications ». Edited by Andrea Bonetti, Roberto Leone, Franco M.Muggia and Stephen B.Howell. Humana Press. Book Series: Cancer Drug Discovery and Development. Published: 2009

Chapitres:

- *Laparoscopically assisted heated Intraoperative Intraperitoneal Chemotherapy (HIPEC): technical aspects and pharmacokinetics data.* Ferron G, Gesson-Paute A, Gladieff L, **Thomas F**, Chatelut E, Querleu D. Pages: 343-351
- *Optimising carboplatin dose using patient characteristics and therapeutic drug monitoring.* Pétain A, Schmitt A, **Thomas F**, Chevreau C, Chatelut E. Pages: 373-378

OS 3. Update of the chapter “Platinum drugs” of the “DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology” textbook with Pr Jan Beumer and Pr Etienne Chatelut.

OV : Ouvrages de vulgarisation (ou chapitres de ces ouvrages)

- 1) Ouvrage pédagogique de pharmacocinétique rédigé sous l'égide du GEPK, coordonné par Etienne Chatelut. « Pharmacocinétique : Les Fondamentaux ». Rédaction de 2 chapitres. Publié en 2018. Elsevier.

Patents

1. Roche case: 24729

European Application No. 08161804.3

Registration date: 05.08.2008

Abstract: The application is directed to the genes GSTA4, CRYAB, PRDX2, NUPR1, ELF3, EPHX1, TBL1X, ABCC5, CEBPD, SMARCA4, ABCC1, INHBB, TP53BP2, THBS1, SERPINE2, AMIGO2, LEPREL1, VEGFC, HSPA2 as expression markers for the treatment of head and neck tumours with Tarceva.

Selection criterion: Differential expression in tumors of responders vs. non-responders.

2. Roche case: 25169

European Application No. 0816812.6

Registration date: 05.08.2008

Abstract: UGT1A isoforms as predictive biomarkers for the treatment of neck and head cancer with Tarceva.

3. Roche case 25170

European Application No. 08161818.3

Registration date: 05.08.2008

Abstract: Cyclin-dependent kinase 2-interacting protein (CINP) as predictive marker for the treatment of neck and head cancer with Tarceva.

INV : Invited conferences as speaker

- INV 1. Congrès de Physiologie, de Pharmacologie et Thérapeutique, Montpellier, France, 2006.**
« La cystatine C, marqueur de l'élimination rénale des médicaments ». **F. Thomas.**
- INV 2. 27^{èmes} Journées du GPCO, Nîmes, France, Novembre 2010.** « PK/PD/PGx des inibs ».
- INV 3. ASIO (Association des Internes en Oncologie), Carcassonne, France, Avril 2011.**
« Pharmacocinétique et Pharmacogénétique des TKI » et « Généralités sur la Pharmacogénétique »
- INV 4. 4th European Symposium on Ovarian Cancer. Reims, France, Juin 2011.** “Pharmacokinetics and Pharmacogenomics of new drugs in ovarian cancer ».
- INV 5. 8^{èmes} Journées du Cancéropôle GSO – Montpellier - 12 Octobre 2012 :** Un point sur l'avancée et le contexte scientifique de l'étude PHACS : Pharmacologie de l'Hormonothérapie en situation Adjuvante dans le Cancer du Sein.
- INV 6. 36^{èmes} Journées de la Société Française de Sénologie et de Pathologie Mammaire. Toulouse, Novembre 2014.** « Pharmacogénomique des médicaments anti-cancéreux »
- INV 7. ASIO (Association des Internes en Oncologie), Toulouse, France, 7 Avril 2016.** « Etudes PK/PD dans le cadre du développement des anticancéreux »
- INV 8. Workshop SIRIC Cancer, IRCM Montpellier Janvier 2017.** « Pharmacologie constitutionnelle des inhibiteurs de tyrosine kinase : des sources de variabilité au suivi thérapeutique pharmacologique ». Interactions médicamenteuses.
- INV 9. 3rd U-PGx Personalized Medicine Day, 17 novembre 2017, Toulouse, France.** « La thérapie personnalisée basées sur la pharmacogénétique : niveaux de preuve et recommandations du Réseau français de pharmacogénétique (RNPGx) »
- INV 10. 17th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, September 2019, Foz do Iguassu, Brésil.** “ Exposure-response relationships of commonly used Mabs in oncology.”
- INV 11. Atelier du GPCO “The challenging issue of CYP2D6 interpretation”, 10 mars 2020, Nîmes.**
“Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study.”

ACTI : Communications avec actes dans un congrès international

(L'auteur souligné est celui qui a présenté les travaux)

- ACTI 1. International Meeting on Innovative Approaches in Head and Neck Oncology, 2007, Barcelona, Spain.** Investigation of predictive factors of response in patients with squamous-cell carcinoma of the head and neck (SCCHN) given neo-adjuvant erlotinib before surgery, updated results of a single institution experience. Benlyazid A, Thomas F, Sarini J, Rives M, Hamelin D, Courbon F, et al. Abstract in Radiotherapy and Oncology. 2007;82:S31-S2.
- ACTI 2. European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care. Stockholm, SWEDEN SEP 23-27, 2011:** “Application of Population PK-PD Methods in Oncology “. Chatelut E, Schmitt A, White-Koning M, **Thomas F**. Abstract in: European Journal of Cancer. 2011;47:S30-S.
- ACTI 3. 14th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Rotterdam, The Netherlands, 2015.** Inhibition of OCT-2, MATE1 and MATE-2K as a possible mechanism of drug interaction between pazopanib and cisplatin. Sauzay C, Hennebelle I, Imbs DC, Deluche T, White-Koning M, Chatelut E, Thomas F. Abstract in: Ther Drug Monit:
- ACTI 4. 14th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Rotterdam, The Netherlands, 2015.** Lethal toxicity of 5-fluorouracil in the era of personalized therapy: discovery of a novel mutation disrupting the dihydropyrimidine deshydrogenase activity. F Thomas, I Hennebelle, S Marsili, C Dhelens, C Garnier Tixidre, A Bonadona, N Penel, A Goncalves, Jp Delord, C Toulas, E Chatelut. Abstract in: Ther Drug Monit:

ACTN : Communications avec actes dans un congrès national

- ACTN 1. Congrès de Physiologie, de Pharmacologie et Thérapeutique, Poitiers, France, 2014.** « Individualisation du carboplatine et marqueurs pharmacogénétiques associés à la toxicité dans le cadre du protocole TICE (tumeurs germinales réfractaires). » Thomas F, Bauriaud M, Imbs DC, Chatelut E, Marsili S, Hennebelle I, Massart C, Broutin S, Lotz JP, Hulin A, Delva R, Boisdron-Celle M, Flechon A, Guitton J, Gravis G, Ciccolini J, Bay JO, GrossGoupil M, Filleron T, Chevreau C. Abstract in: Fundamental & Clinical Pharmacology. 2014;28:18-

COM : Communications orales sans actes dans un congrès international ou national

- COM 1. 26th winter meeting of the EORTC-PAMM group, Arcachon, France, 2005.** “Cystatin c as a new covariate to predict the elimination of drugs: application to carboplatin and topotecan”. F Thomas, S Séronie-Vivien, A Hoppe, JP Delord, L Gladieff, I Lochon, R Bugat, E Chatelut.
- COM 2. 26th winter meeting of the EORTC-PAMM group, Arcachon, France, 2005.** “In vivo and in vitro enhanced antitumor activity of Oxaliplatin in combination with cetuximab (C225), a chimeric monoclonal antibody anti-epidermal growth factor receptor on a panel of human colorectal tumour xenografts”. JP Delord, D Balin-Gauthier, Ph Rochaix, V Mallard, **F Thomas**, I Hennebelle, R Bugat, P Canal, CB Allal

- COM 3.** 15th PAGE (Population Approach Group in Europe) meeting, Bruges, 2006. "Cystatin C as a new covariate to predict the renal elimination of drugs". F Thomas, S Séronie-Vivien, F Bouissou, M Tafani, JP Delord, L Gladiéff, E Chatelut.
- COM 4.** 114^{ème} Congrès De La Société Française D'oto-Rhino-Laryngologie Et De Chirurgie De La Face Et Du Cou. Paris, France 2007. « Utilisation de la tomographie par émission de positons dans l'évaluation précoce de la réponse aux thérapeutiques ciblant l'EGFR dans les carcinomes épidermoïdes ORL. » Vergez S, Delord J, Allal B, Courbon F, Cazelles O, Rochaix P, **Thomas F**, Serrano E.
- COM 5.** 10th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy. Verone, Italie, Décembre 2007. "Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intra-operative intraperitoneal Chemotherapy (HIPEC): an experimental study." Ferron G, Gesson-Paute A, **Thomas F**, Cohen de Lara E, Chatelut E, Querleu D.
- COM 6.** 9^{èmes} Journées du Cancéropôle GSO – Limoges - Octobre 2013. « Individualisation du carboplatine et marqueurs pharmacogénétiques associés à la toxicité dans le cadre du protocole TICE (tumeurs germinales réfractaires). » Thomas F, Bauriaud M, Imbs DC, Chatelut E, Marsili S, Hennebelle I, Massart C, Broutin S, Lotz JP, Hulin A, Delva R, Boisdrón-Celle M, Flechon A, Guitton J, Gravis G, Ciccolini J, Bay JO, Gross-Goupil M, Filleron T, Chevreau C.
- COM 7.** 36th winter meeting of the EORTC-PAMM group, Marseille 2015. Inhibition of OCT-2, MATE1 and MATE-2K as a possible mechanism of drug interaction between pazopanib and cisplatin. Sauzay C, Hennebelle I, Imbs DC, Deluche T, White-Koning M, Chatelut E, **Thomas F**.
- COM 8.** 36th winter meeting of the EORTC-PAMM group, Marseille 2015. Lethal toxicity of 5-fluorouracil in the era of personalized therapy: discovery of a novel mutation disrupting the dihydropyrimidine deshydrogenase activity. F Thomas, I Hennebelle, I Lochon, C Dhelens, C Garnier Tixidre, A Bonadona, N Penel, A Goncalves, Jp Delord, C Toulas, E Chatelut.
- COM 9.** XV^{ies} Journées du GPCO, Toulouse nov 2016. Suivi thérapeutique du carboplatine dans le protocole d'intensification de dose pour le traitement du cancer du testicule (protocole TICE): analyse pharmacocinétique du carboplatine. Moeung S, Chevreau C, Marsili S, Fizazi K, Broutin S, Flechon A, Guitton J, Delva R, Boisdrón-Celle M, Gravis G, Ciccolini J, Lotz JP, Bay JO, Gross-Goupil M, Chatelut E, **Thomas F**.
- COM 10.** 1st Annual European Congress on Genitourinary Malignancies, Juin 2017, Prague. Individualization of high dose carboplatin based on therapeutic drug monitoring (TDM) for the treatment of testicular germ cell tumors (TICE protocol): Results of a multicenter phase II study. Fabienne Thomas, Christine Chevreau, Sotheara Moeung, Christophe Massard, Aude Flechon, Remy Delva, Gwenaelle Gravis, Jean-Pierre Lotz, Jacques-Olivier Bay, Etienne Chatelut.

AFF : Communications par affiche dans un congrès international ou national

- AFF 1.** 16th EORTC - National Cancer Institute (NCI); Symposium on "Molecular Targets and Cancer Therapeutics", Geneva, Switzerland, 2004. "In vivo and in vitro enhanced antitumor activity of Oxaliplatin in combination with cetuximab (C225), a chimeric monoclonal antibody anti-epidermal growth factor receptor on a panel of human colorectal tumour xenografts." D Balin-Gauthier, JP Delord, Ph Rochaix, V Mallard, **F Thomas**, I Hennebelle, R Bugat, P Canal, CB Allal.

- AFF 2.** **96th Annual Meeting of the American Association for Cancer Research, Anaheim, April 2005.** PET-FDG assessment of biological volume response allows early assessment of Erlotinib (Tarceva) anti-proliferative effects in patients pending first-line surgical management of head and neck squamous cell carcinoma. F Courbon, **F Thomas**, J Sarini, A Benlyazid, P Rochaix, JP Delord.
- AFF 3.** **15th annual course of the International Federation of ORL Societies. April 9th- 17th 2005.** Neoadjuvant erlotinib (Tarceva, OSI 774) prior to first line surgery for HNSCC: the Claudius Regaud experience. A Benlyazid, J Sarini, **F Thomas**, I Hennebelle, M Rives, E Chatelut, C Allal, P Rochaix, F Courbon, JP Delord.
- AFF 4.** **41th ASCO Annual meeting, Orlando, USA, 2005.** Cystatin C as a new covariate to predict the elimination of drugs: application to carboplatin and topotecan". E Chatelut, S Séronie-Vivien, **F Thomas**, A Hoppe, JP Delord, L Gladieff, F Dalenc, R Bugat. Abstract in Journal of Clinical Oncology. 2005;23(16):142S-S.
- AFF 5.** **42th ASCO Annual meeting, Atlanta, USA, 2006.** Neo-adjuvant treatment with erlotinib in squamous cell carcinoma head and neck (SCCHN) patients before surgery provides an opportunity to find predictive factors of response. J-P Delord, **F Thomas**, A Benlyazid, J Sarini, M Rives, M Begue, F Courbon, P Rochaix. Abstract in Journal of Clinical Oncology. 2006;24(18):283S-S.
- AFF 6.** **44th ASCO Annual meeting, USA, 2008.** Gene expression profiling on pre- and post-erlotinib tumors from HNSCC patients. Delord J, **Thomas F**, Allal C, Delmar P, McLoughlin P, Rochaix P. Abstract in Journal of Clinical Oncology. 2008;26(15).
- AFF 7.** **33rd ESMO Congress, Stockholm, Suède, 12-16 Septembre 2008.** Gene Expression profiling on pre and post erlotinib tumors from HNSCC patients. Delord JP, **Thomas F**, Delmar PD, McLoughlin P, Rochaix P. Abstract in Annals of Oncology. 2008;19:218-9.
- AFF 8.** **6th International Workshop on Peritoneal Surface Malignancy, Lyon, France, 17-19 novembre 2008.** Increased tissue diffusion of oxaliplatin during laparoscopically assisted versus open hyperthermic intraperitoneal chemotherapy (HIPEC): An experimental study. G Ferron, **F Thomas**, A Gesson-Paute, M Hristova, I Lochon, E Chatelut. **29th winter meeting of the EORTC-PAMM group, Palermo, Italia, 2008.** Population pharmacokinetics of erlotinib and its pharmacokinetics/pharmacodynamics relationships. **F Thomas**, JP Delord, P Rochaix, I Hennebelle, A Benlyazid, J Sarini, P Canal, R Bugat, E Chatelut.
- AFF 10.** **99th Annual Meeting of the American Association for Cancer Research, San Diego, April 2008.** Preclinical results and clinical results of pilot study assessing the effects of Erlotinib in patients with squamous cell carcinoma of head and neck: rationale for using PET scan as an efficient tool for early assessment of response. S Vergez, JP Delord, F Courbon, P Rochaix, **F Thomas**, O Caselles, B Allal.
- AFF 11.** **45th ASCO Annual meeting, Atlanta, USA, 2009.** Pharmacokinetic and biological study of erlotinib in children as monotherapy for refractory brain tumors or with radiation for newly diagnosed brain stem gliomas. Geoerger B, Hargrave D, **Thomas F**, Andreiuolo F, Varlet P, Frappaz D, et al. Abstract in Journal of Clinical Oncology. 2009;27(15).
- AFF 12.** **41st Congress of the International Society of Paediatric Oncology, 5-9 October 2009, Sao Paulo, Brazil.** Biological and pharmacokinetic study of erlotinib in children as monotherapy for refractory brain tumors or with radiation for newly diagnosed pontine gliomas. Andreiuolo F, Geoerger B, Hargrave D, **Thomas F**, Varlet P, Frappaz D, et al. Abstract in Pediatric Blood & Cancer. 2009;53(5):825-.

- AFF 13. 31th PAMM-EORTC meeting, Toulouse, France, 2010.** “Role of UGT1A in the tumour resistance to erlotinib”. Frantz E, Vergez S, Couderc B, Hennebelle I, Allal Ben C, Delord JP, **Thomas F**.
- AFF 14. 6es Journées du Cancéropôle Grand Sud-Ouest, 2010.** Evaluation of TEP-FDG in the early evaluation of EGFR inhibitors in ORL epidermoid. Vergez S, Delord JP, **Thomas F**, Rochaix P, Cazelles O, Brillouet S, et al. Abstract in Bulletin Du Cancer. 2010;97:S49-S.
- AFF 15. 7es Journées du Cancéropôle Grand Sud-Ouest, 2011.** Role of CAR xenobiotic receptors (Constitutive Androstane Receptor, NR113) and PXR (Pregnane X receptor, NR112) in the cellular response to anticancerous agents. Leguelinel G, Planque C, Kantar J, Poujol S, **Thomas F**, Joubert D, et al. Abstract in Bulletin Du Cancer. 2011;98:S57-S.
- AFF 16. 9^{èmes} Journées du Cancéropôle GSO – Limoges - Octobre 2013.** « Evaluation du BGJ398 dans le traitement des carcinomes épidermoïdes des voies aérodigestives supérieures : rôle de l’amplification de FGFR1 ? » Sadeler A, **Thomas F**, Hennebelle I, Lacroix-Triki M, Thibault B, Delord JP.
- AFF 17. 9^{èmes} Journées du Cancéropôle GSO – Limoges - Octobre 2013.** « Irreversible Hepatotoxicity after administration of Trabectedin to a Pleiomorphic Sarcoma Patient with ABCC2 rare polymorphism: a case report.” F Thomas, AP Laurenty, E Chatelut, S Bétrian, C Le Guellec, I Hennebelle, S Le Guellec, C Chevreau.
- AFF 18. 10^{èmes} Journées du Cancéropôle GSO – Toulouse - Octobre 2014.** Implication des transporteurs renaux dans l’interaction pazopanib / cisplatine. Sauzay Chloé, hennebelle I, imbs DC, deluche Thomas, Chatelut E, **Thomas F**.
- AFF 19. 36th winter meeting of the EORTC-PAMM group, Marseille 2015.** Lethal toxicity of 5-fluorouracil in the era of personalized therapy: discovery of a novel mutation disrupting the dihydropyrimidine deshydrogenase activity. F Thomas, I Hennebelle, I Lochon, C Dhelens, C Garnier Tixidre, A Bonadona, N Penel, A Goncalves, Jp Delord, C Toulas, E Chatelut.
- AFF 20. 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago, 2013.** A French prospective pilot study for identifying dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients (pts) receiving capecitabine (cap). Etienne-Grimaldi MC, Ferrero JM, **Thomas F**, Bobin-Dubigeon C, Merlin JL, Pinguet F, Ferrand C, Boyer, JC, Romieu G, Bachelot TD, Pivot XB, Dieras V, Largillier R, Mousseau M, Goncalves A, Roche H, Bonnetterre J, De Clercq B, Milano G. Abstract in Journal of Clinical Oncology. 2013;31(15).
- AFF 21. 51th Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago, 2015.** “Exhaustive single nucleotide polymorphism (SNP) analysis of DPYD exome in breast cancer patients (pts) receiving capecitabine.” Etienne-Grimaldi MC, Boyer, JC, Llorca L, Romieu G, Bachelot TD, Dieras V, Merlin JL, Pinguet F, **Thomas F**, Ferrand C, Bobin-Dubigeon C, Pivot XB, Largillier R, Mousseau M, Goncalves A, Roche H, Ciccolini J, Ferrero JM, Milano G. J Clin Oncol 33, 2015 (suppl; abstr 2571).
- AFF 22. 53th Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago, 2017.** Individualization of high dose carboplatin based on therapeutic drug monitoring (TDM) for the treatment of testicular germ cell tumors (TICE protocol): Results of a multicenter phase II study. **Fabienne Thomas**, Sothearea Moeung, Sophie Broutin, Jerome Guitton, Michele Boisdron-Celle, Joseph Ciccolini, Christophe Massard, Aude Flechon, Remy Delva, Gwenaelle Gravis, Jean-Pierre Lotz, Jacques-Olivier Bay, Marine Gross-Goupil, Angelo Paci, Vianney Poinsignon, Karim Fizazi, Thierry Lafont, Isabelle Lochon, Christine Chevreau, Etienne Chatelut. J Clin Oncol 35, 2017 (suppl; abstr 4554)

- AFF 23. San Antonio Breast Cancer Symposium™, December 5-9, 2017.** “Pharmacogenetic determinants of aromatase inhibitors pharmacokinetics and side effects: 6-month results of the adjuvant breast cancer longitudinal PHACS study (NCT01127295)”. **Fabienne Thomas**, Pierre Marquet, Frédéric Pinguet, Melanie White-Koning, Jacques Robert, Naïma Tafzi, Isabelle Solassol, Raymond Despax, Nadia Levasseur, Stephen Ellis, Angélique Massoubre, Litaty Mbatchi, Valérie Le Morvan, Henri Roché, Etienne Chatelut, Alexandre Evrard.
- AFF 24. 2017 San Antonio Breast Cancer Symposium™, December 5-9, 2017.** “Impact of genetic polymorphisms on plasma levels of tamoxifen and its metabolites and toxicity: 6-months results of the adjuvant breast cancer longitudinal PHACS study (NCT01127295)”. Melanie White-Koning, Cécile Arellano, Valérie Le Morvan, Alexandre Evrard, Alicja Puzskiel, Christelle Vachoux, Jérôme Dauba, Philippe Houyau, Muriel Poublanc, Jacques Robert, Jean-Christophe Boyer, Henri Roché, **Fabienne Thomas**, Etienne Chatelut.
- AFF 25. 27th Annual Meeting of the Population Approach Group in Europe, 2018 May 29th-June 1st; Montreux, Switzerland** A Puzskiel, C Arellano, H Roché, C Vachoux, A Evrard, V Le Morvan, E Chatelut, F Thomas, M White-Koning. Quantitative evaluation of the impact of CYP2D6 genetic polymorphisms on pharmacokinetics of tamoxifen and its metabolites in breast cancer patients.
- AFF 26. 28th Annual Meeting of the Population Approach Group in Europe, 2019; Stockholm, Sweden.** “Population pharmacokinetic analysis of tamoxifen and its six metabolites in breast cancer patients: Quantification of the impact of genetic polymorphisms and co-medications on tamoxifen metabolism.” A Puzskiel, C Arellano, C Vachoux, A Evrard, V Le Morvan, JC Boyer, J Robert, C Delmas, F Dalenc, M Debled, L Venat-Bouvet, W Jacot, E Suc, I Sillet Bach, T Filleron, H Roché, E Chatelut, **F Thomas**, M White-Koning
- AFF 27. 17th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, 2019, Foz do Iguassu, Brésil.** “A consensual panel for NGS in pharmacogenetics from the French National Network of Pharmacogenetics (RNPgX).” N Picard, C Barin-LeGuellec, S Cunat, T De Beaumais, A Evrard, X Fonrose, MC Gagnieu, E Gauthier, V Haufroid, F Lamoureux, L Mbatchi, C Narjoz, L Payen, S Quaranta, **F Thomas**, C Versuyft, MA Lorient, JC Boyer.